TAVOCEPT Trademark

Trademark Overview

On Tuesday, July 19, 2022, a trademark application was filed for TAVOCEPT with the United States Patent and Trademark Office. The USPTO has given the TAVOCEPT trademark a serial number of 97510148. The federal status of this trademark filing is REVIVED - AWAITING FURTHER ACTION as of Tuesday, April 8, 2025. This trademark is owned by Lantern Pharma Inc.. The TAVOCEPT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, medications used in chemotherapeutic regimens for the treatment of cancer; pharmaceutical preparations for the treatment of cancer
tavocept

General Information

Serial Number97510148
Word MarkTAVOCEPT
Filing DateTuesday, July 19, 2022
Status616 - REVIVED - AWAITING FURTHER ACTION
Status DateTuesday, April 8, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 14, 2024

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, medications used in chemotherapeutic regimens for the treatment of cancer; pharmaceutical preparations for the treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, August 9, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameLantern Pharma Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressDallas, TX 75201
Party NameLantern Pharma Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDallas, TX 75201

Trademark Events

Event DateEvent Description
Wednesday, May 3, 2023ASSIGNED TO EXAMINER
Friday, July 22, 2022NEW APPLICATION ENTERED
Tuesday, August 9, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, June 7, 2023NON-FINAL ACTION WRITTEN
Wednesday, June 7, 2023NON-FINAL ACTION E-MAILED
Wednesday, June 7, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, September 21, 2023ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Thursday, September 21, 2023ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Thursday, September 21, 2023ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Friday, November 17, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, November 17, 2023TEAS PETITION TO REVIVE RECEIVED
Friday, November 17, 2023PETITION TO REVIVE-GRANTED
Friday, November 17, 2023NOTICE OF REVIVAL - E-MAILED
Friday, November 17, 2023NOTICE OF REVIVAL - E-MAILED
Monday, April 8, 2024ASSIGNED TO LIE
Tuesday, April 9, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, April 9, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, April 9, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 24, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 14, 2024PUBLISHED FOR OPPOSITION
Tuesday, May 14, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 9, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, April 7, 2025TEAS PETITION TO REVIVE RECEIVED
Monday, April 7, 2025NOTICE OF REVIVAL - E-MAILED
Monday, April 7, 2025PETITION TO REVIVE-GRANTED
Monday, April 7, 2025SOU EXTENSION RECEIVED WITH TEAS PETITION
Monday, April 7, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, April 7, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, April 7, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, February 10, 2025ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 10, 2025ABANDONMENT - NO USE STATEMENT FILED

Related Keywords

tavocept pharmaceutical treatment cancer preparations regimens used namely medications chemotherapeutic